sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma

Endocrinology

Volumn 145, Issue 2, 2004, Pages 817-822

  Ye, Caisheng ^a,b   Feng, Chong ^a,b   Wang, Shenming ^a   Wang, Kent Z Q ^b   Huang, Nancy ^b   Liu, Xiaoning ^b   Lin, Yongjie ^a   Li, Mengfeng ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER GROWTH; CELL LINE; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG SCREENING; EMBRYO; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; FEMALE; FOLLICULAR CARCINOMA; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KIDNEY CELL; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; THYROID CARCINOMA; UMBILICAL VEIN;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; ANTIGENS, CD31; CELL DIVISION; CELL LINE; EMBRYO; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SOLUBILITY; THYROID NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0842334575     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-1106     Document Type: Article

References (48)

1. Folkman J 1990 What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
2. Kerbel R, Folkman J 2002 Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
4. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N 1998 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343
5. Schlessinger J, Ullrich A 1992 Growth factor signaling by receptor tyrosine kinases. Neuron 9:383-391
6. Kliche S, Waltenberger J 2001 VEGF receptor signaling and endothelial function. IUBMB Life 52:61-66
7. Fong GH, Rossant J, Gertsenstein M, Breitman ML 1995 Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70
8. Itoh K, Fukuda K, Matsuzaki T, Takao S, Ohyama M 1989 Human endothelial cell growth factors derived from thyroid anaplastic cell carcinoma. Laryngoscope 99:533-537
9. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M 1999 Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 30:891-897
10. Klein M, Picard E, Vignaud JM, 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41-49
11. Tuttle RM, Fleisher M, Francis GL, Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737-1742
12. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976
13. Ishiwata T, Iino Y, Takei H, Oyama T, Morishita Y 1998 Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 5:1343-1348
14. Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R 1996 Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 63:95-98
15. Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De Rosa G, Salvatore G, Fusco A, Persico MG, Viglietto G 1999 Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 18:4860-4869
16. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY 2000 Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128:1059-1066
17. Kendall RL, Thomas KA 1993 Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709
18. Kendall RL, Wang G, Thomas KA 1996 Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324-328
19. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M 1996 Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7:213-221
20. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT 1992 The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991
21. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P 1992 Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586
22. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT 1998 Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95:8795-8800
23. Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A, Crystal RG 1998 Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9:823-833
24. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N 2000 Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60:2169-2177
25. Shiose S, Sakamoto T, Yoshikawa H, Hata Y, Kawano Y, Ishibashi T, Inomata H, Takayama K, Ueno H 2000 Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci 41:2395-2403
26. Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H 2000 Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7:978-985
27. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, Curiel DT 2001 Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 7:2057-2066
28. Goretzki PE, Frilling A, Simon D, Roeher HD 1990 Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118: 48-63
29. Danos O, Mulligan RC 1988 Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460-6464
30. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M 1990 Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5:519-524
31. Auerbach R, Auerbach W, Polakowski I 1991 Assays for angiogenesis: a review. Pharmacol Ther 51:1-11
32. Kuzuya M, Kinsella JL 1994 Induction of endothelial cell differentiation in vitro by fibroblast-derived soluble factors. Exp Cell Res 215:310-318
33. Waltenberger J, Mayr U, Frank H, Hombach V 1996 Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28:1523-1529
34. Attia MA, Weiss DW 1966 Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26:1787-1800
35. Weidner N, Semple JP, Welch WR, Folkman J 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8
36. Ye C, Feng C, Wang S, Liu X, Lin Y, Li M 2002 Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 143:3522-3528
37. Li M, Huang X, Zhu Z, Wong M, Watkins S, Zhao Q, Herberman R, Gorelik E 2001 Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J Immunother 24:472-481
38. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D'Amato R, Folkman J, Mulligan RC 2001 Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98:4605-4610
39. Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T, He TC 2001 Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 1:149-162
40. Hawley RG 2001 Progress toward vector design for hematopoietic stem cell gene therapy. Curr Gene Ther 1:1-17
41. Tian GG, Dawson NA 2001 New agents for the treatment of renal cell carcinoma. Expert Rev Anticancer Ther 1:546-554
42. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N 1996 The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 15:4919-4927
43. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS 2002 VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398
44. Li M, Huang X, Zhu Z, Zhao Q, Wong M, Gorelik E 2002 The therapeutic efficacy of angiostatin against weakly-and highly-immunogenic 3LL tumors. In Vivo 16:577-582
45. O'Reilly MS 2002 Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin Cancer Res 8:3309-3310
46. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR 1998 Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291
47. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E 2002 Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 62:5727-5735
48. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S 2000 Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60:2190-2196